British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 ...

Having scored approval for Nucala in COPD, GSK has signed a $12 billion deal to strengthen the pharma’s offering for the respiratory condition.

GSK is turning to a China-based biotechnology company in search of its next blockbuster medicine, announcing Monday a broad drugmaking alliance with Hengrui Pharma that could be worth billions of ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and inflammation.

GSK is taking to the airwaves to talk RSV, presenting a TV special about how the pathogen has affected athletes in the upcoming National Senior Games.

Hengrui Pharma partners with GSK to develop 12 innovative medicines, enhancing COPD treatment and expanding global growth opportunities.

Drugmaker GSK will be paid up to £372million after settling a patent row over Covid vaccines in the US. The London-listed pharmaceuticals giant – previously known as Glaxosmithkline – and ...

As you might know, GSK plc (LON:GSK) recently reported its interim numbers. GSK reported UK£16b in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of ...